BEGIN:VCALENDAR
VERSION:2.0
PRODID: -//Q4 Inc.//EN
METHOD:PUBLISH
BEGIN:VTIMEZONE
TZID:America/New_York
X-LIC-LOCATION:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:19700308T020000
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=2SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:19701101T020000
RRULE:FREQ=YEARLY;BYMONTH=11;BYDAY=1SU
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
ORGANIZER:MAILTO:no-reply@q4inc.com
DTSTART;TZID="America/New_York":20221206T083000
DTEND;TZID="America/New_York":20221206T093000
LOCATION:
UID:9921e128-2ba0-4b91-a577-ae6ff76ec1d6
DTSTAMP:20260513T091254
SUMMARY:Equillium & Ono Pharmaceuticals Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
DESCRIPTION: View More Information: https://www.equilliumbio.com/investors/events-and-presentations/event-details/2022/Equillium-and-Ono-Pharmaceuticals-Announce-Exclusive-Option-and-Asset-Purchase-Agreement-for-the-Development-and-Commercialization-of-Itolizumab/default.aspx
URL;VALUE=URI:https://www.equilliumbio.com/investors/events-and-presentations/event-details/2022/Equillium-and-Ono-Pharmaceuticals-Announce-Exclusive-Option-and-Asset-Purchase-Agreement-for-the-Development-and-Commercialization-of-Itolizumab/default.aspx
PRIORITY:5
CLASS:PUBLIC
END:VEVENT
END:VCALENDAR